Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage

Stroke

Volumn 39, Issue 6, 2008, Pages 1730-1734

  Delgado, Pilar ^a,c   Cuadrado, Eloy ^a   Rosell, Anna ^a   Alvarez Sabin, Jose ^a   Ortega Aznar, Arantxa ^b   Hernandez Guillamon, Mar ^a   Penalba, Anna ^a   Molina, Carlos A ^a   Montaner, Joan ^a  

^a Neurovascular Research Laboratory   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Apoptosis; Edema; Fas ligand; Fas receptor; Intracerebral hemorrhage; Soluble Fas; Stroke

Indexed keywords

FAS ANTIGEN; FAS LIGAND; BIOLOGICAL MARKER; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FAS PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANKIN SCALE; RISK FACTOR; STATISTICAL ANALYSIS; BLOOD; BRAIN; BRAIN EDEMA; BRAIN INFARCTION; DISEASE COURSE; DOWN REGULATION; METABOLISM; MIDDLE AGED; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; REFERENCE VALUE; UPREGULATION; VASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; BIOLOGICAL MARKERS; BRAIN; BRAIN EDEMA; BRAIN INFARCTION; CEREBRAL HEMORRHAGE; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DISEASE PROGRESSION; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; TOMOGRAPHY, X-RAY COMPUTED; UP-REGULATION;

EID: 46249112504     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.500876     Document Type: Article

References (23)

1. Mutlu N, Berry RG, Alpers BJ. Massive cerebral hemorrhage: clinical and pathological correlations. Arch Neurol. 1963;8:644-661.
2. Matsushita K, Meng W, Wang X, Asahi M, Asahi K, Moskowitz MA, Lo EH. Evidence for apoptosis after intracerebral hemorrhage in rat striatum. J Cereb Blood Flow Metab. 2000;20:396-404.
3. Nakashima K, Yamashita K, Uesugi S, Ito H. Temporal and spatial profile of apoptotic cell death in transient intracerebral mass lesion of the rat. J Neurotrauma. 1999;16:143-151.
4. Qureshi AI, Ling GS, Khan J, Suri MF, Miskolczi L, Guterman LR, Hopkins LN. Quantitative analysis of injured, necrotic, and apoptotic cells in a new experimental model of intracerebral hemorrhage. Crit Care Med. 2001;29:152-157.
5. Qureshi AI, Suri MF, Ostrow PT, Kim SH, Ali Z, Shatla AA, Guterman LR, Hopkins LN. Apoptosis as a form of cell death in intracerebral hemorrhage. Neurosurgery. 2003;52:1041-1047.
6. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997; 326:1-16.
7. Nagata S, Golstein P. The Fas death factor. Science. 1995;267: 1449-1456.
8. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:2706-2713.
9. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS, Antel JP. Multiple sclerosis: Fas signaling in oligoden-drocyte cell death. J Exp Med. 1996;184:2361-2370.
10. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med. 1996;184:1513-1518.
11. Beer R, Franz G, Schopf M, Reindl M, Zelger B, Schmutzhard E, Poewe W, Kampfl A. Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat. J Cereb Blood Flow Metab. 2000;20:669-677.
12. Tarkowski E, Rosengren L, Blomstrand C, Jensen C, Ekholm S, Tarkowski A. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke. 1999;30:321-327.
13. Sairanen T, Karjalainen-Lindsberg ML, Paetau A, Ijas P, Lindsberg PJ. Apoptosis dominant in the peri-infarct area of human ischaemic stroke: a possible target of antiapoptotic treatments. Brain. 2006;129:189 -199.
14. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
15. Gebel JM, Sila CA, Sloan MA, Granger CB, Weisenberger JP, Green CL, Topol EJ, Mahaffey KW. Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. Stroke. 1998;29: 1799-1801.
16. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuc-carello M, Khoury J. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996;27:1304-1305.
17. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5.
18. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37:1399-1406.
19. Carhuapoma JR, Wang PY, Beauchamp NJ, Keyl PM, Hanley DF, Barker PB. Diffusion-weighted MRI and proton MR spectroscopic imaging in the study of secondary neuronal injury after intracerebral hemorrhage. Stroke. 2000;31:726-732.
20. Orakcioglu B, Fiebach JB, Steiner T, Kollmar R, Juttler E, Becker K, Schwab S, Heiland S, Meyding-Lamade UK, Schellinger PD. Evolution of early perihemorrhagic changes: ischemia vs. edema: an MRI study in rats. Exp Neurol. 2005;193:369-376.
21. Schellinger PD, Fiebach JB, Hoffmann K, Becker K, Orakcioglu B, Kollmar R, Juttler E, Schramm P, Schwab S, Sartor K, Hacke W. Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? Stroke. 2003;34:1674-1679.
22. Martin-Villalba A, Hahne M, Kleber S, Vogel J, Falk W, Schenkel J, Krammer PH. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. 2001;8:679-686.
23. Ackery A, Robins S, Fehlings MG. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma. 2006;23:604-616.